U.S. FDA Approves Zongertinib
United States Food and Drug Administration approved zongertinib (Hernexeos) as first-line targeted therapy for adults with advanced non-squamous non-small cell lung cancer (NSCLC) having HER2/ERBB2 tyrosine kinase domain mutations. A tyrosine kinase inhibitor, it blocks enzymes that transmit cell-growth signals, preventing cancer proliferation. Earlier used after progression on prior therapy, it showed ~76% tumour reduction in untreated patients versus 30–45% with standard treatment.
The Hindu